By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Science Briefing
  • Medicine
  • Biology
  • Engineering
  • Environment
  • More
    • Dentistry
    • Chemistry
    • Physics
    • Agriculture
    • Business
    • Computer Science
    • Energy
    • Materials Science
    • Mathematics
    • Politics
    • Social Sciences
Notification
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Personalize
Science BriefingScience Briefing
Font ResizerAa
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Search
  • Quick Access
    • Home
    • Contact Us
    • Blog Index
    • History
    • My Saves
    • My Interests
    • My Feed
  • Categories
    • Business
    • Politics
    • Medicine
    • Biology

Top Stories

Explore the latest updated news!

Today’s Political Science Science Briefing | March 25th 2026, 1:00:12 pm

Today’s Neurology Science Briefing | March 25th 2026, 1:00:12 pm

Today’s Renewable Energy Science Briefing | March 25th 2026, 1:00:12 pm

Stay Connected

Find us on socials
248.1KFollowersLike
61.1KFollowersFollow
165KSubscribersSubscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress

Home - Pharmacology - The Unreliable Mind: Questioning the Specificity of EEG Neurofeedback

Pharmacology

The Unreliable Mind: Questioning the Specificity of EEG Neurofeedback

Last updated: March 25, 2026 2:34 am
By
Science Briefing
ByScience Briefing
Science Communicator
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Follow:
No Comments
Share
SHARE

The Unreliable Mind: Questioning the Specificity of EEG Neurofeedback

A new study in Communications Psychology challenges the assumed mechanisms of a common brain-training technique. Using a preregistered, triple-arm, single-session design, researchers evaluated the mechanisms underlying alpha upregulation through EEG neurofeedback. The findings indicate that increases in alpha brainwave power were non-specific, occurring even in control conditions, and point instead to spontaneous, repetition-related brain dynamics rather than a learned, targeted response. This research critically examines the foundational pharmacology and neuropharmacology of biofeedback interventions, suggesting that observed effects may not be due to the specific operant conditioning paradigm but to general neural adaptation processes.

Study Significance: For professionals in pharmacology and neuropharmacology, this study underscores the importance of rigorous, controlled trial design—akin to Phase II clinical trials—for validating the mechanisms of neuromodulatory interventions. It implies that the development of targeted neurotherapeutics and personalized medicine approaches based on neurofeedback may require a more nuanced understanding of baseline brain dynamics and placebo effects. This could shift research priorities towards identifying more reliable biomarkers of brain state change and refining the dose-response relationship in non-pharmacological treatments.

Source →

Stay curious. Stay informed — with Science Briefing.

Always double check the original article for accuracy.

- Advertisement -

Feedback

Share This Article
Facebook Flipboard Pinterest Whatsapp Whatsapp LinkedIn Tumblr Reddit Telegram Threads Bluesky Email Copy Link Print
Share
ByScience Briefing
Science Communicator
Follow:
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Previous Article A repurposed drug offers a lifeline for crush syndrome, a major cause of earthquake mortality
Next Article Liver Transplant for Sclerosing Cholangitis: Long-Term Survival and the Cancer Conundrum
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related Stories

Uncover the stories that related to the post!

A Brain Circuit for Persistent Recklessness

A new target for depression: chronic serotonin receptor activation impairs brain function

A new therapeutic candidate targets fatty liver disease by degrading a key enzyme

A new molecular switch for p53: Targeting the MEIS1-MDM2 axis in cancer therapeutics

Pfizer’s Strategic Pivot: A New Focus for Drug Discovery

Vitamin D emerges as a potential therapeutic agent for uterine fibroids

FDA Approval Signals a New Era for Dwarfism Therapeutics

A Mendelian blueprint for drug safety in pregnancy

Show More

Science Briefing delivers personalized, reliable summaries of new scientific papers—tailored to your field and interests—so you can stay informed without doing the heavy reading.

Science Briefing
  • Categories:
  • Medicine
  • Biology
  • Gastroenterology
  • Social Sciences
  • Surgery
  • Natural Language Processing
  • Engineering
  • Cell Biology
  • Genetics
  • Immunology

Quick Links

  • My Feed
  • My Interests
  • History
  • My Saves

About US

  • Adverts
  • Our Jobs
  • Term of Use

ScienceBriefing.com, All rights reserved.

Personalize you Briefings
To Receive Instant, personalized science updates—only on the discoveries that matter to you.
Please enable JavaScript in your browser to complete this form.
Loading
Zero Spam, Cancel, Upgrade or downgrade anytime!
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?